Table 1.
North American Brain Tumor Consortium phase II trials
| Number of Patients
|
|||
|---|---|---|---|
| Trial | Treatment | Grade III Glioma | Grade IV Glioma |
| 97-01 | Temozolomide and BCNU | 0 | 36 |
| 97-05 | Thymidine and carboplatin | 11 | 34 |
| 98-01 | CPT-11 | 15 | 49 |
| 98-03 | Temozolomide and 13-cis retinoic acid | 47 | 40 |
| 99-01 | R115777 | 22 | 70 |
| 99-04 | Temozolomide and thalidomide | 0 | 44 |
| 99-05 | Fenretinide | 18 | 24 |
| 99-07 | CPT-11 and temozolomide | 9 | 26 |
| 99-08 | Imatinib | 9 | 33 |
| 00-01 | ZD1839 | 15 | 35 |
| 01-01 | CCI-779 | 11 | 30 |
| 01-03 | OSI-774 | 2 | 16 |
Abbreviation: BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea.